Tech Company Financing Transactions
Zucara Therapeutics Funding Round
On 4/3/2020, Zucara Therapeutics secured $21 million in Series A funding from Perceptive Advisors and private investors.
Transaction Overview
Company Name
Announced On
4/3/2020
Transaction Type
Venture Equity
Amount
$21,000,000
Round
Series A
Investors
Perceptive Advisors (Lead Investor) (Chris Garabedian)
Proceeds Purpose
The proceeds from the financing will fund Phase 1 and Phase 2 clinical trials of ZT-01, Zucara's first-in-class drug candidate designed to prevent hypoglycemia in Type 1 Diabetes (T1D), a frequent, unintended consequence of insulin therapy for people with T1D and other types of insulin-dependent diabetes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
661 University Ave. 1300
Toronto ON, M5G 0B7
Canada
Toronto ON, M5G 0B7
Canada
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Michael Riddell
Chief Executive Officer
Michael Midmer
Chief Scientific Officer
Richard Liggins
VP - Regulatory Affairs
Susan Peers
Browse more venture capital transactions:
Prev: 4/3/2020: Concertio venture capital transaction
Next: 4/3/2020: GPB Scientific venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs